Autoantibody Landscape in Patients with Advanced Prostate Cancer.

doi:10.1158/1078-0432.CCR-20-1966

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Autoantibody Landscape in Patients with Advanced Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Dec 2020

Chen William S, Haynes Winston A, Waitz Rebecca, Kamath Kathy, Vega-Crespo Agustin, Shrestha Raunak, Zhang Minlu, Foye Adam, Baselga Carretero Ignacio, Perez Garcilazo Ivan, Zhang Meng, Zhao Shuang G, Sjöström Martin, Quigley David A, Chou Jonathan, Beer Tomasz M, Rettig Matthew, Gleave Martin, Evans Christopher P, Lara Primo, Chi Kim N, Reiter Robert E, Alumkal Joshi J, Ashworth Alan, Aggarwal Rahul, Small Eric J, Daugherty Patrick S, Ribas Antoni, Oh David Y, Shon John C, Feng Felix Y

Abstract excerpt

PURPOSE: Autoantibody responses in cancer are of great interest, as they may be concordant with T-cell responses to cancer antigens or predictive of response to cancer immunotherapies. Thus, we sought to characterize the antibody landscape of metastatic castration-resistant prostate cancer (mCRPC). EXPERIMENTAL DESIGN: Serum antibody epitope repertoire analysis (SERA) was performed on patient serum to identify...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Autoantibodies

Share to Biomarkers, Tumor

Share to Case-Control Studies

Share to Epitopes

Share to Follow-Up Studies

Share to Prognosis

Share to Prostatic Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 32967941
DOI: 10.1158/1078-0432.CCR-20-1966
PMCID: PMC7710628

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Autoantibody Landscape in Patients with Advanced Prostate Cancer.PMID 32967941Read ↗

Autoantibody landscape of advanced prostate cancerSemantic proximity Read ↗

Tumor-associated Antigen Arrays for the Serological Diagnosis of CancerSemantic proximity Read ↗

Recurrent Immunogenic Neoantigens and Their Cognate T-cell Receptors in Treatment-Resistant Metastatic Prostate Cancer.Semantic proximity Read ↗

High-throughput identification of autoantibodies that target the human exoproteomeSemantic proximity Read ↗

Reversing the "cold" tumor microenvironment: the role of neoantigen vaccines in prostate cancer.Semantic proximity Read ↗

Seromic profiling of ovarian and pancreatic cancerSemantic proximity Read ↗

B cell profiles, antibody repertoire and reactivity reveal dysregulated responses with autoimmune features in melanomaSemantic proximity Read ↗

T Cell Receptor repertoire analysis reveals antigenic convergence and immunotherapeutic opportunities in Prostate CancerSemantic proximity Read ↗

Immunodominance Hierarchy of Endogenous BBN963 Bladder Cancer Antigens Remains Stable Under Anti-PD1 and Anti-CTLA4 ImmunotherapySemantic proximity Read ↗

Mapping Tumor Epitope Space by Direct Selection of Single-Chain Fv Antibody Libraries on Prostate Cancer CellsSemantic proximity Read ↗

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer.Semantic proximity Read ↗

An Immunoproteomic Survey of the Antibody Landscape: Insights and Opportunities Revealed by Serological Repertoire ProfilingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.